Scarica l'app Stockscreener
8.83
0.06%
-0.005
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
Seven new 4D Molecular staff receive 66,900 stock units - Stock Titan
Infographic: Study design for ELARA, an open-label, phase 3b trial of aflibercept 8 mg in previously treated patients with neovascular age-related macular degeneration or diabetic macular edema - Nature
FDMT: Gene therapy 4D-150 targets lifelong vision benefit and reduced injections in wet AMD - TradingView
FDMT: 4D-150 gene therapy shows promise for durable wet AMD treatment with strong safety and scalability - TradingView
Insider Sell Alert: David Kirn Sells Shares of 4D Molecular Therapeutics Inc (FDMT) - GuruFocus
4d molecular therapeutics CEO Kirn sells $19,257 in shares By Investing.com - Investing.com South Africa
4d molecular therapeutics CEO Kirn sells $19,257 in shares - Investing.com
Insider David Kirn sells 1,922 4D Molecular (NASDAQ: FDMT) shares - Stock Titan
Monte Rosa (NASDAQ: GLUE) CEO sells 5,466 shares under Rule 10b5-1 plan - Stock Titan
[144] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Monte Rosa Therapeutics (GLUE) CSO sells 6,000 shares under 10b5-1 plan - Stock Titan
Number of shareholders of 4D Molecular Therapeutics, Inc. – NASDAQ:FDMT - TradingView
Opus Genetics Slides Ahead of June Test - Bez Kabli
IonQ Aktie: Two Sigma kauft 2,17 Millionen Aktien - Finanztrends
4D Molecular Therapeutics (FDMT) Gains 1.6% as Stock Holds Above SupportThematic ETF Flow - The Legal Advocate
4DMT to Participate in Upcoming Investor Conferences - The Globe and Mail
Pittsburgh Post-Gazette - FinancialContent
4D Molecular Therapeutics Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
4D Molecular Therapeutics Inc (FDMT): Gene Therapy Stock Made for You? - Insider Monkey
4D Molecular Therapeutics, Inc.Common Stock (NQ: FDMT - FinancialContent
5 Best Gene Therapy Stocks to Buy in 2026 - Insider Monkey
FDMT: Pivotal global trials advance a disruptive, lifelong gene therapy for retinal disease - TradingView
About Us - FinancialContent
User | mammothtimes.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
User | malvern-online.com4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy - MarketBeat
4D Molecular Therapeutics Inc. (FDMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
RA Capital affiliates report 9.99% of 4D Molecular (NASDAQ: FDMT) via warrants and shares - Stock Titan
BVF affiliates report 5.35M 4D shares (FDMT) and 8.48M pre-funded warrants - Stock Titan
Biotech 4D Molecular Therapeutics grants 141,100 RSUs to new employees - Stock Titan
Fat Pitch Financials4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
[EFFECT] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
Chardan Capital Maintains 4D Molecular Therapeutics (FDMT) Buy Recommendation - MSN
FDMT: 4D-150's phase III progress and robust data position it as a potential game-changer in retinal gene therapy - TradingView
State Street (FDMT) discloses 5.3% holdings — 2.7M shares reported on 03/31/2026 - Stock Titan
Analysts Have Made A Financial Statement On 4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) First-Quarter Report - simplywall.st
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates - Yahoo Finance
Analyst Reiterates Buy on 4D Molecular Therapeutics as Wet AMD Gene Therapy Advances, Keeps $36 Price Target Unchanged - TipRanks
4D Molecular Therapeutics (NASDAQ:FDMT) Issues Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
4D Molecular Therapeutics, Inc. Stock 12‑Month Price Target Cut to $27.62, Implies 178% Upside - TradingView
4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
4D Molecular Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
4D Molecular Therapeutics (NASDAQ: FDMT) files $400M shelf registration - Stock Titan
Wet AMD gene therapy moves ahead; 4DMT targets 2027 Phase 3 data - Stock Titan
[10-Q] 4D Molecular Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
4D Molecular Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
4D Molecular (NASDAQ: FDMT) details Q1 loss and cash runway to 2028 - Stock Titan
FDMT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
4D Molecular Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
4DMT management to present at BofA, RBC healthcare conferences - Stock Titan
4D Molecular Therapeutics (FDMT) to Release Quarterly Earnings on Thursday - MarketBeat
[ARS] 4D Molecular Therapeutics, Inc. SEC Filing - Stock Titan
1.04%
0.76%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):